Design of highly active analogues of the pyrrolo[1,2-a]benzimidazole antitumor agents

Journal of Medicinal Chemistry

Volumn 42, Issue 17, 1999, Pages 3324-3333

  Craigo, William A ^a   LeSueur, Benjamin W ^a   Skibo, Edward B ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; DIHYDROLIPOAMIDE DEHYDROGENASE; FLAVOPIRIDOL; RORIDIN A;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; HUMAN; HUMAN CELL; HYDROGEN BOND; MOUSE; NONHUMAN; STEREOCHEMISTRY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BENZIMIDAZOLES; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM TRANSPLANTATION; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033606944     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990029h     Document Type: Article

References (26)

1. Skibo, E. B.; Schulz, W. G. Pyrrolo[1,2-α]benzimidazole-Based Aziridinyl Quinones. A New Class of DNA Cleaving Agent Exhibiting G and A Base Specificity. J. Med. Chem. 1993, 36, 3050-3055.
2. Schulz, W. G.; Nieman, R. A.; Skibo, E. B. Evidence for DNA Phosphate Backbone Alkylation and Cleavage by Pyrrolo[1,2-α]benzimidazoles, Small Molecules Capable of Causing Sequence Specific Phosphodiester Bond Hydrolysis. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 11854-11858.
3. Skibo, E. B. The Discovery of the Pyrrolo[1,2-α]benzimidazole Antitumor Agents - The Design of Selective Antitumor Agents. Curr. Med. Chem. 1996, 2, 900-931.
4. Skibo, E. B. Pyrrolobenzimidazoles in cancer treatment. Exp. Opin. Ther. Patents. 1998, 8, 673-701.
5. Skibo, E. S.; Gordon, S.; Bess, L.; Boruah, R.; Heileman, J. Studies of Pyrrolo[1,2-α]benzimidazole Quinone DT-Diaphorase Substrate Activity, Topoisomerase II Inhibition Activity, and DNA Reductive Alkylation. J. Med. Chem. 1997, 40, 1327-1339.
6. Skibo, E. B.; Islam, I.; Heileman, M. J.; Schulz, W. G. Structure - Activity Studies of Benzimidazole-Based DNA-Cleaving Agents. Comparison of Benzimidazole, Pyrrolobenzimidazole and Tetrahydropyridobenzimidazole Analogues. J. Med. Chem. 1994, 37, 78-92.
7. Zhou, R.; Skibo, E. B. Chemistry of the Pyrrolo[1,2-α]benzimidazole Antitumor Agents: Influence of the 7-Substituent on the Ability to Alkylate DNA and Inhibit Topoisomerase II. J. Med. Chem. 1996, 39, 4321-4331.
8. Schulz, W. G.; Islam, E.; Skibo, E. B. Pyrrolo[1,2-α]benzimidazole-Based Quinones and Iminoquinones. The Role of the 3-Substituent on Cytotoxicity. J. Med. Chem. 1995, 38, 109-118.
9. Hollingshead, M.; Plowman, J.; Alley, M.; Mayo, J.; Sausville, E. Relevance of Tumor Models in Anticancer Drug Development. Contributions to Oncology; Krager Verlag: Germany, 1999.
10. Skibo, E. B.; Islam, I.; Schulz, W. G.; Zhou, R.; Bess, L.; Boruah, R. The Organic Chemistry of the Pyrrolo[1,2-α]benzimidazole Antitumor Agents. An Example of Rational Drug Design. Synlett 1996, 297-309.
11. Hollingshead, M. G.; Alley, M. C.; Camalier, R. F.; Abbott, B. J.; Mayo, J. G.; Malspeis, L.; Grever, M. R. Life Sci. 1995, 27, 131-141.
12. Sedlacek, H. H.; Czech, J.; Naik, R.; Kaur, G.; Worland, P.; Losiewicz, M.; Parker, B.; Carlson, B.; Smith, A.; Senderowicz, A.; Sausville, E. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. 1996, 9, 1143-1168.
13. Schrump, D. S.; Matthews, W.; Chen, G. A.; Mixon, A.; Altorki, N. K. Flavopiridol Mediates Cell Cycle Arrest and Apoptosis in Esophageal Cancer Cells. Clin. Cancer Res. 1998, 4, 2885-2890.
14. Paull, D. K.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and Analysis of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
15. Alvarez, M.; Robey, R.; Sandor, V.; Nishiyama, K.; Matsumoto, Y.; Paull, K.; Bates, S.; Fojo, T. Using the national cancer institute anticancer drug screen to assess the effect of mrp expression on drug sensitivity profiles. Mol. Pharmacol. 1998, 54, 802-814.
16. Riley, R. J.; Workman, P. DT-diaphorase and Cancer Chemotherapy. Biochem. Pharmacol. 1992, 43, 1657-1669.
17. Marin, A.; deCerain, A. L.; Hamilton, E.; Lewis, A. D.; Martin-ezPenuela, J. M.; Idoate, M. A.; Bello, J. DT-diaphorase and cytochrome B-5 reductase in human lung and breast tumours. Br. J. Cancer 1997, 76, 923-929.
18. Rauth, A. M.; Goldberg, Z.; Misra, V. DT-diaphorase: Possible roles in cancer chemotherapy and carcinogenesis. Oncol. Res. 1997, 9, 339-349.
19. Beall, H. D.; Winski, S.; Swann, E.; Hudnott, A. R.; Cotterill, A. S.; OSullivan, N.; Green, S. J.; Bien, R.; Siegel, D.; Ross, D.; Moody, C. J. Indolequinone antitumor agents: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H: quinone oxidoreductase, and in vitro cytotoxicity. J. Med. Chem. 1998, 41, 4755-4766.
20. Wu, K. B.; Knox, R.; Sun, X. Z.; Joseph, P.; Jaiswal, A. K.; Zhang, D.; Deng, P. S. K.; Chen, S. Catalytic properties of NAD(P)H: quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch. Biochem. Biophys. 1997, 347, 221-228.
21. Kelsey, K. T.; Ross, D.; Traver, R. D.; Christiani, D. C.; Zuo, Z. F.; Spitz, M. R.; Wang, M.; Xu, X.; Lee, B. K.; Schwartz, B. S.; Wiencke, J. K. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br. J. Cancer 1997, 76, 852-854.
22. Beall, H. D.; Mulcahy, R. T.; Siegel, D.; Traver, R. D.; Gibson, N. W.; Ross, D. Metabolism of Bioreductive Antitumor Compounds by Purified Rat and Human DT-Diaphorase. Cancer Res. 1994, 54, 3196-3201.
23. Reynolds, R. C. Aziridines. In Cancer Chemotherapeutic Agents; Foye, W. O., Ed.; American Chemical Society: Washington, DC, 1995; pp 187-197.
24. Morimoto, M.; Fukui, M.; Ohkubo, S.; Tamaoki, T.; Tomita, F. Tetrocarcins, New Antitumor Antibiotics. 3. Antitumor Activity of Tetrocarcin A. J. Antibiot. (Tokyo) 1982, 35, 1033-1037.
25. Tamaoki, T.; Kasai, M.; Shirahata, K.; Ohkubo, S.; Morimoto, M.; Mineura, K.; Ishii, S.; Tomita, F. Tetrocarcins, Novel Antitumor Antibiotics. II. Isolation, Characterization and Antitumor Activity. J. Antibiot. (Tokyo) 1980, 33, 946-950.
26. Höjeberg, B.; Blomberg, K.; Stenberg, S.; Lind, C. Biospecific Adsorption of Hepatic DT-Diaphorase on Immobilized Dicoumarol. Arch. Biochem. Biophys. 1981, 207, 205-216.